DOCSLIB.ORG

Disclosure Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Disclosure Index 2020 DISCLOSURE INDEX DISCLOSURE INDEX This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The AANEM is accredited by the ACCME to provide continuing medical education for physicians. It is the policy of the AANEM to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All participating speakers, planning committee members, and authors are required to disclose to the program audience any financial relationships with proprietary entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients that is related to the subject matter of this program. Spouse/partner relationships with commercial interests are also disclosed. Disclosure information was reviewed in advance in order to manage and resolve any possible conflicts of interest. All conflicts of interest have been resolved in accordance with ACCME Standards for Commercial Support. 2020 Annual Meeting Disclosure Information Disclosure information for all faculty, planning committee members and staff (and their spouse/partner) participating in this activity and/or the planning of this activity is provided below. FACULTY Financial Full Name Degree Disclosure Commercial Interest Financial Relationship Allen, Jeffrey A. MD No None N/A Allen, Tristin MD No None N/A Amato, Anthony A. MD No None N/A Avila, J. David MD Yes Alnylam Pharmaceuticals, Akcea Therapeutics Speaker Bureau Barnett‐Tapia, Carolina MD YES Takeda, Alexion, CSL Behring Consultant Octapharma, Grifols Research Grants Barrell, Kelsey J. MD Yes Alnylam Pharmaceutical Advisory Board Beydoun, Said R. MD Yes Argenx, UCB, Ra pharma, Catalyst Research Grant Takeda, Akcea, Alnylam, Mitsubishi Tanabe, Grifols, CSL Behring Consultant/Speaker Bilicier, Suur MD No None N/A Bradshaw, Deborah Y. MD No None N/A Bromberg, Mark B. MD Yes Accordant Health Care Medical Consultant Grifols, Alexion Speaker Callaghan, Brian MD No None N/A Cao, Michelle MD No None N/A Cartwright, Michael S. MD No None N/A Comer, Adam D. MD No None N/A Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc, Hansa Medical Ab, Pledpharma, Momenta Pharmaceuticals, Inc., CSL Behring, Sanofi‐ Aventis Recherche & Developpement, Pfizer Inc, Seattle Genetics Inc, Octapharma Ag, Grifols, S.A., Cigna Corporation, Pharnext Sa, Annexon Biosciences, UCB Pharma Inc, Boehringer Ingelheim, Biotest Pharmaceuticals, Inc., Argenx, Cytomx Therapeutics, Passagebio Pharma, Seattle Genetics Inc, Astrazeneca Pharmaceuticals Lp, Genentech Corp, Merrimack Pharmaceuticals, Disarm Therapeutics, Inc, Levicept Cornblath, David R. MD Yes Ltd., Amgen Inc. Consultant/Honoraria Biohaven, Biogen, Takeda, Anelixis, Avexis, Sunovian, Cudkowicz, Merit E. MD Yes Cytokinetics Consultant Day, John W. MD Yes Audentes, Biogen, Ionis Pharmaceuticals, Roche/Genentech Pharmaceuticals, Cytokinetics, Pfizer, AveXis, AMO Pharmaceuticals, Sarepta Therapeutics, Santhera Pharmaceuticals, Scholar Rock Advisory/Consulting Biogen, Ionis Pharmaceuticals, Cytokinetics, Pfizer, Roche Pharmaceuticals, AveXis, Sanofi‐Genzyme, Sarepta Therapeutics, Scholar Rock Grants Del Toro, David R. MD No None N/A Dillingham, Timothy R. MD No None N/A Dolan, Candy MD No None N/A Donofrio, Peter D. MD No None N/A Drachman, Brian MD No None N/A Edmundson, Christyn Ensrud, Erik MD NO None N/A Ferrante, Mark A. MD No None N/A Ferris, Daniel MD Yes Lockheed Martin Corporation and BTemia on exoskeleton research through the University of Florida Research ReWalk Robotics Ltd. Stock Filer, William MD No None N/A Gable, Karissa MD No None N/A Geiger, Christopher MD No None N/A Goyal, Namita MD No None N/A Grant, Peter A. MD No None N/A Greene, Ericka P. MD No None N/A Guidon, Amanda C. MD Yes Alexion Medical Advisory Board Momenta Medical Advisory Board, Consultant GE healthcare Spouse Employment Alexion Pharmaceuticals Inc, Grifols, Jacobus Consulting fees, research funding, Pharmaceutical, Momenta, TRIPHASE Pharma honoraria Solutions LLC, UCB, Becton Dickinson, Kashiv, BPL Guptill, Jeffrey T. MD Yes Pharma Gwathmey, Kelly G. MD Yes Alexion pharmaceuticals Consulting/Speaker honoraria Hehir, Michael K. MD Yes Alexion and Argenx Pharma Consulting Hobson‐Webb, Lisa D. MD No None N/A Jamal, Nasheed I. MD No None N/A Kang, Peter B. MD Yes AveXis/Novartis, ChromaDex Consultant Sarepta Advisory Board Karam, Chafic MD No None N/A Katirji, Bashar MD No None N/A Kazamel, Mohamed MD Yes Akcea Therapeutics Consulting Fees Kesner, Vita G. MD No None N/A Khella, Sami L. MD No None N/A Kimura, Jun MD No None N/A Kolb, Noah A. MD Yes Abalone Bio, Disarm Therapeutics Consultant Kolb, Noah A. MD No None N/A Krzesniak‐Swinarska, Monika MD No None N/A Kwan, Justin Y. MD No None N/A Laughlin, Ruple S. MD No None N/A Levin, Kerry H. MD No None N/A Lewis, Richard A. MD Yes CSL Behring, Argenx, Annexon, Pharnext, Biotest, Takeda, Sanofi, Momenta, Pfizer, Polyneuron, UCB Consultant Akcea, Alnylam Speaker Honoraium Li, Yuebing MD Yes Argenx Inc. Consultant Li, Yuebing MD No None N/A Manousakis, Georgios MD No None N/A Massey, Janice M. MD Yes Revance Pharmaceuticals Clinical Investigator Argex Advisory Board Mathuria, Nilesh MD No None N/A Mauermann, Michelle L. MD Yes Ionis and Alnylam Pharmaceuticals Research Funding Mauermann, Michelle L. MD No None N/A Mauricio, Elizabeth A. MD No None N/A Capricor, Catabasis, Astellas, Santhera, Sarepta, PTC, McDonald, Craig M. MD Yes Eipirium, Italfarmaco Consultant Morris, Jerry MD No None N/A Mozaffar, Tahseen MD Yes Abbvie, Alexion, Amicus, Argenx, Audentes, Sanofi‐ Advisory Boards (travel reimbursement Genzyme, Sarepta, Spark Therapeutics. and honorarium) Alexion, CSL, Grifols, and Sanofi‐Genzyme Speaker's Bureau Alexion, Amicus, Argenx, Audentes, Bristol‐Myers‐ Squib, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi‐Genzyme, Spark Therapeutics, UCB, Valerion, NIH Research Funding Acceleron Safety Monitoring Board Naddaf, Elie MD No None N/A Onofrei, Ligia V. MD No None N/A Pasnoor, Mamatha MD Yes Argenx, Catalyst and CSL Behring Consultant Peltier, Amanda C. MD Yes Alnylam, Akcea, CSL Behring Pharma companies. Consultant Polydefkis, Michael J. MD Yes Akcea, Ionis, Pfizer, Biogen, Vertex and Alnylam. Consultant Pozsgai, Eric MD Yes Sarepta Therapeutics Stock Preston, David C. MD No None N/A CSL Behring, Grifols, Stealth Biotherapeutics, Argnex, Pulley, Michael T. MD Yes BioProducts Laboratory Advisory Boards/Consulting Querol, Luis MD No None N/A Robinson, Lawrence R. MD No None N/A Rubin, Devon I. MD No None N/A Sakamuri, Sarada MD No None N/A Salajegheh, Mohammad K. MD Yes Strongbridge Biopharma Consultant Sanders, Donald B. MD No None N/A Schaublin, Greg A. MD No None N/A Shaibani, Aziz MD No None N/A Shroff, Sheetal MD No None N/A Shy, Michael E. MD No None N/A Simmons, Daniel B. MD No None N/A Singhal, Divya MD No None N/A Smith, Benn E. MD No None N/A So, Yuen T. MD No None N/A Stavros, Kara MD No None N/A Strakowski, Jeffrey A. MD No None N/A Sumner, Charlotte J. MD Yes Avexis, Genentech, Roche, Biogen Advisory Committee (honorarium) Roche Grant Support Swenson, Andrea J. MD No None N/A Tsao, Bryan E. MD No None N/A VanEvery, Loretta M. MD No None N/A Verma, Aparajitha K. MD No None N/A Wolfe, Gil I. MD Yes ArgenX, BPL, UCB/Ra Consultant ArgenX, BPL, UCB/Ra, Alexion, Immunovant Research Support Zaidman, Craig M. MD No None N/A Zhou, Lan MD No None N/A STAFF Financial Full Name Degree Disclosure Commercial Interest Financial Relationship Adkins, Shirlyn JD No None N/A Jones, Shelly No None N/A Ogden, Christy No None N/A Parks, Tracy No None N/A Tiegen, Gwenda No None N/A Planner Financial Full Name Degree Disclosure Commercial Interest Financial Relationship ASIMe, Paradigm Medical Communications, Catalyst Alter, Katharine E. MD Yes Medical Education Honoraria Arvantaj, Ali CAP, CNCT No None N/A Baruah, Gita R. MD No None N/A Bess, Barbara R. MD No None N/A Bierner, Samuel M. MD No None N/A Burgess, Kathleen H. MD No None N/A Carrion‐Jones, Monica J. MD No None N/A Castoro, Ryan DO, MS No None N/A Chandok, Arun K. MD No None N/A Chiodo, Anthony E. MD, MBA No None N/A Craig, Earl J. MD No None N/A Cuchanski, Mathieu DO No None N/A Dombroski, Kristin L. CNCT, RNCST No None N/A Dorman, James R. MD No None N/A Duplechan, Lester S. MD No None N/A Dutton, Rebecca MD No None N/A Farheen, Amtul S. MD No None N/A Filer, William MD No None N/A Fitzpatrick, Kevin F. MD No None N/A Ford, Carrie E. CNCT, R.EP.T., R.NCS.T. No None N/A Galbreath, Andrew DO No None N/A Garcia Santibanez, Rocio Carolina C. MD No None N/A Goyal, Neelam MD No None N/A Haig, Andrew J. MD No None N/A None N/A Hartigan, Anne G. MD No None N/A Haustein, David MD No None N/A Hobson‐Webb, Lisa D. MD Yes Genzyme, a Sanofi Company research support Research Support G1 Therapeutics Spouse Employment Hoyle, J. Chad MD Yes REATA and TAKEDA PI Funding Tocagen Stock Hsu, Philip S. MD No None N/A Juel, Vern C. MD No None N/A Kazamel, Mohamed MD No None N/A Kim, Susan J. DO No None N/A Krzesniak‐Swinarska, Monika MD No None N/A Kwan, Justin Y. MD No None N/A Laughlin, Ruple S. MD No None N/A Ma, Maxwell MD No None N/A Martinez‐Thompson, Jennifer M. MD No None N/A Miller, Matthew E. MD No None N/A Morris, Jerry CNCT, MS, R.NCS.T., FASET No None N/A Morrison, Eric MD No None N/A Nguyen, Gabrielle MD No None N/A Norbury, John W.
Load more

Recommended publications
  • Objectives & Accreditation
    Objectives & Accreditation ACTIVITY FORMAT Live TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. TYPE OF ACTIVITY Live Activity; Application/ Knowledge EDUCATIONAL OBJECTIVES At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families. At the conclusion of this activity, all participants should be able to: Session I: The Impact of Genetics in Lipidology? Apply insight from human population genetics studies to identify novel therapeutic targets for a better understanding for atherosclerotic cardiovascular disease. Describe the current and future technologies available for genetic screen includinghow to apply them in clinical practice both for diagnosis and risk assessment Discuss experimental techniques in development for genetic manipulation to target inherited lipid disorders Keynote I Discuss ApoC3 as both a risk factor for ASCVD and as potential for therapeutic manipulation Session II- Focus on Lipoprotein (a) Discuss the epidemiology of Lipoprotein(a) (LP(a)) for both thrombosis and ASCVD Discuss the pathophysiology of LP(a) and how this impacts increased risk of ASCVD and thrombosis Discuss the status of current and emerging treatment options targeting LP(a) Clinical Lipidology Track- Critically appraise emerging research
    [Show full text]
  • Pioneering New Markets Changing the Standard of Care
    ANNUAL 2020 REPORT Pioneering New Markets Changing the Standard of Care UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 2855 Gazelle Court, Carlsbad, CA 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value ‘‘IONS’’ The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No □ Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • ALEXION PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 ALEXION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-27756 13-3648318 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 121 Seaport Boulevard, Boston, Massachusetts 02210 (Address of principal executive offices, including zip code) (475) 230-2596 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol on which registered Common Stock, par value $0.0001 per share ALXN The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • 1976 3M Medical Solutions Division 2019 Electrocore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2019 electroCore, Inc. 2019 Optinose 1985 Abbott Laboratories, Inc. 2010 Endo Pharmaceuticals 2018 Organogenesis 2013 AbbVie Inc. 2017 Exelixis 2004 Otsuka America Pharmaceutical, Inc. 2021 Adaptive Biotechnologies 2016 Express Scripts Federal Pharmacy 2018 Pacira BioSciences, Inc. 2017 ACADIA Pharmaceuticals, Inc. 2010 Federal Practitioner 2018 Paratek Pharmaceuticals 2020 AcelRx Pharmaceuticals, Inc. 2018 Foundation Medicine, Inc. 1990 Pfizer Pharmaceuticals 2020 Acorda Therapeutics 2021 Frontier Technology Inc. (FTI) 2017 Pharmacyclics, LLC 2019 Aimmune 2020 Fresenius Medical Care North America 2020 RedHill BioPharma 2003 Alcon Laboratories, Inc. 1989 Genentech Inc. 2019 Red One Medical 2019 Alexion Pharmaceuticals, Inc. 2006 Gilead Sciences 2020 Regeneron 2017 Alkermes, Inc. 1983 GLAXOSMITHKLINE 2009 Regenesis Biomedical, Inc. 2019 Alnylam Pharmaceuticals 2013 Golden State Medical Supply, Inc. 2011 Remund Group, LLC 2019 Altarum Institute 2020 GRAIL 2018 Rigel Pharmaceuticals 2020 Amarin Corporation 2019 Greenwich Biosciences 2000 Sanofi 1994 AmerisourceBergen 2013 Gulf Coast Pharmaceuticals Plus, LLC 2020 Seattle Genetics 1992 Amgen 2008 Heritage Health Solutions, Inc. 2004 Siemens Medical Solutions 2020 Amneal Pharmaceutical 2017 Hill-Rom Company 2019 SK Life Science, Inc. 2019 Aptive Resources LLC 2020 Immunomedics 2002 Smith & Nephew, Inc. 2020 The Arbinger Institute 2019 ImmunoVation, LLC 2019 Sobi Inc. 2011 Arbor Pharmaceuticals, LLC 2019 Incyte Corporation 2013 Stryker Orthopaedics 2010 Argentum Medical, LLC 2019 Indivior 2018 Sun Pharmaceutical 2019 ASM Research, LLC 2015 Intercept Pharmaceuticals 1999 Sunovion Pharmaceuticals, Inc. 1986 Astellas Pharma US, Inc. 2019 Ipsen Biopharmaceuticals, Inc. 2016 Taiho Oncology, Inc. 1995 AstraZeneca 2018 IT Cadre 2015 Takeda Oncology 2020 Baudax Bio, Inc.
    [Show full text]
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • Pharma: Strategic Realignment for a 112/113 Better Future Prism / 2 / 2020
    Pharma: Strategic realignment for a 112/113 better future Prism / 2 / 2020 Pharma: Strategic realignment for a better future ... and how the industry will be forced to overcome its hesitation to innovate in operations Ben van der Schaaf, Aurelien Guichard The life sciences sector faces significant impact from Amid the search for COVID-19 – and although the race for treatments and vaccines effective COVID-19 treatments and vaccines, is dominating the headlines, the effect on the industry will the pandemic will have not solely be positive. long-term side effects for the global pharmaceutical In the short term, some companies industry. As our article explains, companies are laying people off and reducing will need to focus on operations, whereas others are change in three areas reallocating resources to focus on (portfolio reprioritization, COVID-19, or even ramping up accelerated R&D and technology efforts in other areas. Stock-market transformation) if they performance has been as diverse are to position (Figure 1). themselves successfully for the future. Organizations need to consider major strategic questions now, to ensure their success in the longer term. The industry is clearly in the middle of the efforts to combat COVID-19: - More than 20 companies are trying to find a treatment with either new or approved drugs1. - More than 15 companies globally are mobilizing resources to develop new vaccines2. - Globally, by the end of May, more than 1,300 clinical trials related to COVID-19 were recruiting patients3. 1. Marketwatch.com, 6 May 2020 2. Drugtargetreview.com, 9 April 2020 3. clintrials.gov, 31 May 2020 Pharma: Strategic realignment for a 114/115 better future Prism / 2 / 2020 2.
    [Show full text]
  • Sample of Current Attendees
    SAMPLE OF CURRENT ATTENDEES TITLE COMPANY Sr Mgr Global Meetings Mgmt Amgen Prin Tradeshow Spec Boston Scientific Events Mgr PR Medical Events Sr Buyer Pharma Ops ITA Group Travel Services Supv Grifols Asia Pacific Pte Ltd Compliance Specialist GCO Spend Jouney Lead Global Mtgs Travel Events UCB Category Project Specialist Roche Events & Travel Mgr Teva Brasil Mgr Event Mgmt Bayer Congress Mgr MediCongress Services Global Events Mgmt Sr Assoc Amgen Assoc Dir Congresses & Events MSD Internal Event Mgr Gilead Sourcing Mgr BMS Dir Sourcing Meeting Alliance Custoerm Srvs Meetings Mgr Eli Lilly & Company Sr Congress Mgr Novartis Pharmaceuticals Sourcing Mgr BCD Meetings & Events Sr Buyer Meetings & Incentives Worldwide Sourcing Mgr American Express GBT Acct Mgr Venue Sourcing Ashfield Meetings & Events Mtg Planner AbbVie Sr Sourcing Mgr CWT Dir Sourcing Planning Partners International Meetings Mgr ACOG Meeting Mgr Pfizer Canada Global Event Lead Astellas Meeting & Events Sanofi Events Specialist Cook Medical Meetings & Events Mgr Pfizer Spain Pfizer Spain Sr Mgr Hotel Procurement Meetings & Incentives WorldWide Inc Event Planner SFU BCcampus Mgr Global Strategic Mtg Mgmt Teva Pharmaceuticals Global Mtgs & Events Virtual Mtgs Specialist AstraZeneca Global Congress Strategy Lead MSD Assoc Dir Congresses & Events Alnylam Pharmaceuticals Event Planner AbbVie Institutional & Scientific Events Coordr Almirall Congress Mgr AO Spine Sr Meeting Planner Medtronic Mgr Global Mtgs Mgmt Alnylam Pharmaceuticals Meeting Planner AbbVie Global Audit Meetings
    [Show full text]
  • View State-Of-The-Art Clinical Symposium Disclosures
    Planning Committee Members The following Planning Committee members have no relevant financial relationship(s) with ineligible companies to disclose. Mastering E/M Changes for 2021 • Antanya Chung-Gardiner, BSc • Melesia Tillman 2021 Access in Rheumatology Planning Committee • Marcus Snow, MD 2021 Fellow-in-Training Educational Session Planning Committee • Nadia Elias, MD • Tate Johnson, MD • Justin Levinson, MD, MBA • Jean Lin, MD, PhD • Megan Lockwood, MD • Tyler Reese, MD • Zahra Rehman, MD • Didem Saygin, MD • Rachel Wallwork, MD 2021 State-of-the-Art Clinical Symposium Planning Committee • Sobia Hassan, MD • Aman Kugasia, MD • Jeanie Lee, MD • Manjari Malkani, MD • Rebecca Manno, MD, MHS The following Planning Committee members have relevant financial relationship(s) with ineligible companies to disclose. 2021 Access in Rheumatology Planning Committee • Christopher Phillips, MD - Pfizer (Self): 5 2021 Fellow-in-Training Educational Session Planning Committee • Mary Mamut, DO - Bendcare (Self): 8 2021 State-of-the-Art Clinical Symposium Planning Committee • Rohit Aggarwal, MD, MS - AbbVie, Amgen, , Genzyme, , Novartis, Roche, Sandoz, UCB (Self): 1, 5, 2; AdMIRx, Inc. / Now Q-32 (Self): 5, 2; Alexion (Self): 5; Argenx (Self): 5; AstraZeneca (Self): 5; Boehringer Ingelheim (BI) (Self): 5; Bristol-Myers Squibb(BMS) (Self): 5, 2; Corbus (Self): 5; CSL Behring (Self): 1, 5; EMD Serono (Self): 5, 2; Genentech (Self): 2; Janssen (Self): 5; Kezar (Self): 5; Kyverna (Self): 5; Mallinckrodt (Self): 1, 2; Octapharma (Self): 1, 5; Orphazyme (Self): 1; Pfizer (Self): 5, 2; Scipher Medicine: 5 • Narender Annapureddy, MD, MS - Medpage (Self): 1, Expert Reviewers for the ACR Reading Room section of MedPage Today. • Lianne Gensler, MD - AbbVie (Self): 1, 5; Eli Lilly (Self): 5; Gilead: 5; GSK (Self): 5; Janssen (Self): 5; Novartis (Self): 5; Pfizer (Self): 5, 2; UCB: 5 Faculty The following Faculty members have no relevant financial relationship(s) with ineligible companies to disclose.
    [Show full text]
  • Pushing the Limits: Being Innovative in a Regulated Industry
    ISPE Boston Area Chapter Presents: Pushing the Limits: Being Innovative in a Regulated Industry Thursday, November 15, 2018 5:30 pm to 8:30 pm Alnylam 300 Third Street THANK YOU TO OUR PROGRAM SPONSOR Cambridge, MA 02142 EVENT INFORMATION: Join the ISPE Boston Area Chapter for an open forum on innovation. Push your own limits by participating in our pre-program activity with pharma colleagues while enjoying refreshments and a cash bar. Please have valid I. D. ready for a security checkpoint. Walk-ins are still welcome to register onsite. PROGRAM SUMMARY: Innovation comes in many forms ranging from scientific breakthroughs to new technologies and processes. This panel discussion will focus on innovation, and how it impacts the phases of the drug development lifecycle through regulatory compliance. The intent of this discussion is to allow for an interactive look into how innovation can be applied in a regulated field by providing an open forum for the moderator and audience to interact with industry leaders. If you want to better understand how to integrate innovation in your business, or the effects of innovation on your business, this panel will provide much-needed insight. By having people walking the walk of innovation from Development, Engineering, Manufacturing and Regulatory Affairs, we will be able to look to interdependencies, conflict, and synergies of innovative products. Topics will range from technical, personnel, and regulatory decisions needed to incorporate innovation into your business. WHO SHOULD ATTEND: Development, Engineering, Manufacturing, Quality Assurance and Regulatory Affairs personnel. Anybody that wants to better understand how to develop and execute teams when implementing innovative platforms or technologies.
    [Show full text]
  • October 2019
    J.P. Morgan Healthcare Conference Presented by Brett P. Monia, Ph.D. Chief Executive Officer January 15, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority owned affiliate. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2018, and its most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available at www.ionispharma.com. In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]